Article: FibroGen Closes $56.5 Million Private Financing; Japanese, Finnish and U.S. Investors Led by Franklin Templeton and American Express Financial Advisors.

Business Editors and Health/Medical Writers

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 28, 2000

FibroGen, Inc., announced today the completion of a $56.5 million private placement of convertible preferred stock. Investors, including a syndicate representing Finland, Japan, Taiwan, and current FibroGen stockholders, were led in the financing by Franklin Templeton Investments and American Express Financial Advisors (AMEX).

"The success of this financing allows FibroGen the opportunity to aggressively expand activities manufacturing scale up and commercialization of our synthetic collagens and gelatin and to accelerate the research and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!